Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 300

Sort by

Sort Order Select

Journal Articles

Association of socioeconomic indicators with survival in chronic myeloid leukemia: A retrospective analysis

Blood (2025) 146 (Supplement 1): 4636.

https://doi.org/10.1182/blood-2025-4636

Published: 2025

Journal Articles

Longitudinal analysis of first and subsequent-line tyrosine kinase inhibitor use in chronic myeloid leukemia: A 16-year single-center experience

Moaath Mustafa Ali, Emily Zabor, Kamilla Abdurakhmanov, Hadil Zureigat, Ahmed Nabil, Muaz Alsabbagh Alchirazi, Aastha Dhakal, Ali Mushtaq, Naveen Rehman, Bryan Berube, Akriti Jain, John Molina, Sophia Balderman, Abhay Singh, Aaron Gerds, Anjali Advani, Hetty Carraway, Matt Kalaycio, Sudipto Mukherjee

Blood (2025) 146 (Supplement 1): 2012.

https://doi.org/10.1182/blood-2025-2012

Published: 2025

Journal Articles

Cardiovascular disease risk scores as predictors of cardiovascular disease and heart failure in allogeneic hematopoietic cell transplant survivors

Victoria Stepanyants, Xuefei Jia, William Liu, Matt Kalaycio, Ronald Sobecks, Claudio Brunstein, Andrew Trunk, Christina Ferraro, Kayla Giannetti, Arianne Clare Agdamag, Betty K. Hamilton

Blood (2025) 146 (Supplement 1): 2488.

https://doi.org/10.1182/blood-2025-2488

Published: 2025

Journal Articles

A pilot study of nicotinamide riboside supplementation in allogeneic bone marrow transplantation

Ronald Sobecks, Navneet Majhail, Xiaorong Gu, Xuefei Jia, Megan Molnar, John Desamito, Dongxu Jiang, Kacey O'Donnell, Songa Bae, Craig Sauter, Andrew Trunk, Deepa Jagadeesh, Matt Kalaycio, Betty K. Hamilton, Claudio Brunstein, Jaroslaw Maciejewski, Babal Jha

Blood (2025) 146 (Supplement 1): 2437.

https://doi.org/10.1182/blood-2025-2437

Published: 2025

Journal Articles

Outcomes of Accelerated and Blast Phase Chronic Myeloid Leukemia at a Tertiary Center

Ahmed N Mohamed, Hadil Zureigat, Muaz Alsabbagh Alchirazi, Aastha Dhakal, Ali Mushtaq, Naveen Rehman, Bryan Berube, Sneha Govande, Emily C. Zabor, Akriti G. Jain, John C. Molina, Sophia Balderman, Abhay Singh, Aaron T. Gerds, Anjali S. Advani, Hetty E. Carraway, Matt Kalaycio, Sudipto Mukherjee, Moaath K. Mustafa Ali

Blood (2024) 144 (Supplement 1): 6610.

https://doi.org/10.1182/blood-2024-210152

Published: 2024

Journal Articles

Factors Associated with Platelet Engraftment Following Allogeneic Hematopoietic Cell Transplantation

Andrew D. Trunk, Hong Li, Matt Kalaycio, Ronald Sobecks, Claudio Brunstein, Craig S. Sauter, Betty K. Hamilton

Blood (2024) 144 (Supplement 1): 3488.

https://doi.org/10.1182/blood-2024-204051

Published: 2024

Journal Articles

Assessment of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplant When Comparing Treatment with and without Post-Transplant Cyclophosphamide

Daniel P. Nurse, Wei Wei, Amanda Burns, Joseph Farinella, Deepa Jagadeesh, Robert M. Dean, Rabi Hanna, Seth J Rotz, Aaron T. Gerds, Claudio Brunstein, Matt Kalaycio, Craig S. Sauter, Betty K. Hamilton, Ronald Sobecks

Blood (2024) 144 (Supplement 1): 7383.

https://doi.org/10.1182/blood-2024-202626

Published: 2024

Journal Articles

Outcomes of Second-Line Tyrosine Kinase Inhibitors after First-Line Imatinib in Chronic Myelogenous Leukemia: A Retrospective Cohort Study

Muaz Alsabbagh Alchirazi, Hadil Zureigat, Ahmed N Mohamed, Aastha Dhakal, Ali Mushtaq, Naveen Rehman, Bryan Berube, Sneha Govande, Emily C. Zabor, Akriti G. Jain, John C. Molina, Sophia Balderman, Abhay Singh, Aaron T. Gerds, Anjali S. Advani, Hetty E. Carraway, Matt Kalaycio, Sudipto Mukherjee, Moaath K. Mustafa Ali

Blood (2024) 144 (Supplement 1): 6597.

https://doi.org/10.1182/blood-2024-206448

Published: 2024

Journal Articles

Impact of Non- ABL1 Mutations on Outcomes in Patients with Chronic Myeloid Leukemia

Akriti G. Jain, Joy Nakitandwe, Krishna Desai, Genevieve M Crane, David S. Bosler, Jill O'Brien, Moaath K. Mustafa Ali, John C. Molina, Sophia Balderman, Anjali S. Advani, Hetty E. Carraway, Aaron T. Gerds, Abhay Singh, Matt Kalaycio, Sudipto Mukherjee

Blood (2024) 144 (Supplement 1): 3153.

https://doi.org/10.1182/blood-2024-209165

Published: 2024

Journal Articles

Cardiovascular Profile of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia: A 16-Year Observational Study

Blood (2024) 144 (Supplement 1): 1777.

https://doi.org/10.1182/blood-2024-212146

Published: 2024

Journal Articles

Prevalence and Outcomes of Opportunistic Infections in Steroid Refractory Graft Versus Host Disease Patients Treated with Ruxolitinib, Ibrutinib, and Belumosudil

Victoria Stepanyants, Hong Li, Danielle Cenin, Jessi Edwards, Claudio Brunstein, Matt Kalaycio, Ronald Sobecks, Craig S. Sauter, Betty K. Hamilton

Blood (2024) 144 (Supplement 1): 2145.

https://doi.org/10.1182/blood-2024-199329

Published: 2024

Journal Articles

Influence of Pre-Transplant Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation

Ronald Sobecks, Hong Li, Danielle Cenin, Seema Patel, Jesse Edwards, Stephanie Farlow, Amelia Bragg, Rabi Hanna, Seth J Rotz, Deepa Jagadeesh, Aaron T. Gerds, Robert M. Dean, Brad Pohlman, Betty K. Hamilton, Claudio Brunstein, Matt Kalaycio, Craig S Sauter

Blood (2023) 142 (Supplement 1): 3621.

https://doi.org/10.1182/blood-2023-187071

Published: 2023

Journal Articles

Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin Lymphoma and Multiple Myeloma Treated with CAR T-Cell Therapies

Agrima Mian, Danai Dima, Betty K. Hamilton, Allison Winter, Jack Khouri, Louis S. Williams, Shahzad Raza, Deepa Jagadeesh, Aaron T. Gerds, Robert M. Dean, Matt Kalaycio, Claudio Brunstein, Craig S Sauter, Faiz Anwer, Brian T. Hill, Paolo Caimi

Blood (2023) 142 (Supplement 1): 7399.

https://doi.org/10.1182/blood-2023-188712

Published: 2023

Journal Articles

Day 100 Risk Assessment Tool Predicts 1 Year Survival in Allogeneic Hematopoietic Cell Transplant Patients

Joseph Farinella, Lauren M Granat, Hong Li, Sharon M Caroniti, Pranay S. Hegde, Matt Kalaycio, Ronald Sobecks, Claudio Brunstein, Craig S Sauter, Betty K. Hamilton

Blood (2023) 142 (Supplement 1): 3725.

https://doi.org/10.1182/blood-2023-189629

Published: 2023

Journal Articles

Chip-Derived Vs De Novo Treatment-Related Myeloid Neoplasms after Autologous Stem Cell Transplant for Lymphoid Disorders

Hussein Awada, Carmelo Gurnari, Valeria Visconte, Teodora Kuzmanovic, Hassan Awada, James R. Cook, David S. Bosler, Brian J. Bolwell, Ronald M. Sobecks, Matt Kalaycio, Jaroslaw P. Maciejewski

Blood (2022) 140 (Supplement 1): 298–299.

https://doi.org/10.1182/blood-2022-167886

Published: 2022

Journal Articles

The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 10592–10593.

https://doi.org/10.1182/blood-2022-168433

Published: 2022

Journal Articles

Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant

Hussein Awada, Adel Hajj Ali, Beth M. Faiman, Allison Winter, Sandra Mazzoni, Christy J. Samaras, Craig S. Sauter, Willem J. van Heeckeren, Robert M. Dean, Brad Pohlman, Brian T. Hill, Jason Valent, Ronald M. Sobecks, Louis S. Williams, Deepa Jagadeesh, Betty K. Hamilton, Matt Kalaycio, Faiz Anwer, Jack Khouri

Blood (2022) 140 (Supplement 1): 10596–10597.

https://doi.org/10.1182/blood-2022-168810

Published: 2022

Journal Articles

Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab

Seema Patel, Danielle Cenin, Donna Corrigan, Betty K. Hamilton, Matt Kalaycio, Ronald M. Sobecks, Faiz Anwer, Jack Khouri, Robert M. Dean, Allison Winter, Deepa Jagadeesh, Brad Pohlman, Brian T. Hill, Craig S. Sauter, Paolo F. Caimi

Blood (2022) 140 (Supplement 1): 5073–5074.

https://doi.org/10.1182/blood-2022-169809

Published: 2022

Journal Articles

Long-Term Outcomes of Delayed Neutrophil Engraftment Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 12924–12925.

https://doi.org/10.1182/blood-2022-170385

Published: 2022

Journal Articles

Long-Term Outcomes of Autologous Hematopoietic Cell Transplant of Multiple Myeloma: A 10 Year Follow up Study

Blood (2022) 140 (Supplement 1): 12920–12921.

https://doi.org/10.1182/blood-2022-168262

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Association of socioeconomic indicators with survival in chronic myeloid leukemia: A retrospective analysis

Longitudinal analysis of first and subsequent-line tyrosine kinase inhibitor use in chronic myeloid leukemia: A 16-year single-center experience

Cardiovascular disease risk scores as predictors of cardiovascular disease and heart failure in allogeneic hematopoietic cell transplant survivors

A pilot study of nicotinamide riboside supplementation in allogeneic bone marrow transplantation

Outcomes of Accelerated and Blast Phase Chronic Myeloid Leukemia at a Tertiary Center

Factors Associated with Platelet Engraftment Following Allogeneic Hematopoietic Cell Transplantation

Assessment of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplant When Comparing Treatment with and without Post-Transplant Cyclophosphamide

Outcomes of Second-Line Tyrosine Kinase Inhibitors after First-Line Imatinib in Chronic Myelogenous Leukemia: A Retrospective Cohort Study

Impact of Non- ABL1 Mutations on Outcomes in Patients with Chronic Myeloid Leukemia

Cardiovascular Profile of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia: A 16-Year Observational Study

Prevalence and Outcomes of Opportunistic Infections in Steroid Refractory Graft Versus Host Disease Patients Treated with Ruxolitinib, Ibrutinib, and Belumosudil

Influence of Pre-Transplant Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation

Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin Lymphoma and Multiple Myeloma Treated with CAR T-Cell Therapies

Day 100 Risk Assessment Tool Predicts 1 Year Survival in Allogeneic Hematopoietic Cell Transplant Patients

Chip-Derived Vs De Novo Treatment-Related Myeloid Neoplasms after Autologous Stem Cell Transplant for Lymphoid Disorders

The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant

Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab

Long-Term Outcomes of Delayed Neutrophil Engraftment Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Long-Term Outcomes of Autologous Hematopoietic Cell Transplant of Multiple Myeloma: A 10 Year Follow up Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only